Chronic Obstructive Pulmonary Disease Market Analysis and Forecast till 2025 including Leading Players: AstraZenca Plc., GlaxoSmithKline, Novartis AG, Boehringer Ingelheim, Teva Pharmaceuticals, Almirall

Chronic obstructive pulmonary disease (COPD), is an obstructive disease which is characterised by the long-term difficulty in breathing. Chronic obstructive pulmonary disease is the fifth-leading cause of death globally and COPD is one of the leading cause of morbidity and mortality worldwide. According to World Health Care (WHO), COPD mainly occurs mostly in the under developed countries.

Also, in 2016 the global burden of diseases study reported 251 million cases of COPD globally. Chronic obstructive pulmonary disease is characterised by the symptoms such as; shortness of breath, frequent coughing, wheezing, tightness in the chest and cough with/without Sputum production.

Asia Pacific is relied to grow faster during the forecast period. Increasing number of patients with COPD, rising intake of tobacco by the youths, and increased awareness for the use of generic drugs to boost chronic obstructive pulmonary disease market during upcoming years.

For more Professional and Technical Insights Request Sample @
https://www.polarismarketresearch.com/industry-analysis/global-chronic-obstructive-pulmonary-disease-market/request-for-free-sample

Chronic obstructive pulmonary disease, is majorly influenced by the factors such as increasing air pollution, poorly vented heating and cooking smoke, long exposures to the irritants that cause inflammatory response to the lungs. It can be prevented by controlling the risk factors like reducing smoking, and improving the indoor and outdoor air quality.

However, chronic obstructive pulmonary disease is not curable, but can be controlled with various types of drugs. Hence, considering this factor the major players are continuously focusing on the new drug development and approvals. For instance, recently Umeclidinium Bromide by GlaxoSmithKline is considered to be a promising molecule for treating COPD.

Chronic Obstructive Pulmonary Disease Market Taxonomy: -

The market size is segmented on the basis of cancer type, diagnostic techniques, treatment type, end users, and geography.

On the basis of drug type, market is segmented into:
• Phosphodiestrase-4 Inhibitors
• Long-Acting Bronchodilators
• Short-Acting Bronchodilators
• Methylxanthines
• Corticosteroids

On the basis of product type, market is segmented into:
• Inhalers
• Dry Powder Inhalers
• Metered Dose Inhalers
• Soft Mist Inhalers
• Nebulizers
• Ultrasonic Nebulizers
• Jet Nebulizers

Geographically, the market share is categorized into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Increased expenditure on R&D for developing new and effective drugs to lead the global chronic obstructive pulmonary disease market in North America.
North America is expected to dominate the market over the forecast period. North America holds major share owing to the ongoing clinical trials by the increasing R&D investments by the major players and the government. While, increasing awareness for the use of drugs would also spur the Chronic Obstructive Pulmonary Disease Market of North America. Also, Europe region has comparatively large number of population suffering from COPD.

Make an Enquiry for 'Queries' related to this research report @
https://www.polarismarketresearch.com/industry-analysis/global-chronic-obstructive-pulmonary-disease-market/inquire-before-buying

Key players in the Chronic Obstructive Pulmonary Disease Market are:
• AstraZenca Plc.
• GlaxoSmithKline
• Novartis AG
• Boehringer Ingelheim
• Teva Pharmaceuticals
• Almirall
• Ache Laboratorios Famaceuticos
• Ario Pharma
• Asmacure
• BioMarck Pharmaceuticals
• Aquinox Pharmaceuticals
• Astellas Pharma

Rising prevalence of chronic obstructive pulmonary disorder in the developing countries and changing lifestyle will support the growth of market.

The global chronic obstructive pulmonary disorder market is primarily driven by increasing number of patients suffering from COPD. Figures for 2015 state that approximately 3.1 million deaths were reported due to COPD which amount to 5% of the deaths globally. In addition, factors that augment the growth of Chronic Obstructive Pulmonary Disease Market size are rising government initiatives for developing new drugs and promoting easy practices for drug approval in various regions.

On the other hand, increasing technological advancements for developing effective products including nebulizers will also spur this market. Likewise, increasing tobacco consumption is expected to accelerate the market growth during the forecast period.

Partial TOC of Chronic Obstructive Pulmonary Disease Market: -

1. Industry snapshot
2. Ecosystem analysis
3. Market Dynamics
4. Industry analysis - Porter's five force
5. Degree of competition
6. Market PEST Analysis
7. Market Value Chain Analysis
8. Industry Trends
9. Competitive Ranking Analysis

About Us:
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world. We strive to provide our customers with updated information on innovative technologies, high growth markets, emerging business environments and latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced and extremely qualified team of experts comprising SMEs, analysts and consultants, we at Polaris endeavor to deliver value-added business solutions to our customers.

Contact Us:
Mr. Neel
Corporate Sales, USA
Polaris Market Research and Consulting
Phone: 1-646-568-9980
Email: sales@polarismarketresearch.com
Web: www.polarismarketresearch.com

This release was published on openPR.